The Pistoia Alliance's Methods Database Project is addressing a longstanding challenge in analytical science by creating a standardized, vendor-independent format for the digital exchange of High-Performance Liquid Chromatography–Ultraviolet (HPLC-UV) methods. Built on the Allotrope Framework and the Pistoia Alliance Data Platform, the project enables machine-readable, semantically consistent method transfer between different Chromatography Data Systems (CDS), fully aligned with FAIR (Findable, Accessible, Interoperable, and Reusable) data principles. A pilot implementation with Merck Sharp & Dohme LLC and GSK was able to demonstrate the successful two-way exchange of standardized HPLC instructions across instruments and sites. This validated the technical feasibility of digital method sharing and set the stage for wider industry adoption. This collaborative, pre-competitive effort delivers multiple tangible advantages: SciY is a software brand that provides a broad spectrum of scientific software solutions across the entire life sciences spectrum. SciY is a concept developed by Bruker BioSpin which emerged from collaborative efforts with various brand-neutral software partners, including Mestrelab, Arxspan, Optimal Industrial Technologies, Optimal Industrial Automation, and ZONTAL. Fueled by a shared progressive entrepreneurial vision and the necessity to recognize the benefits and added value of a unified market presence and a diversified brand portfolio, these partners united their individual ventures under one collective brand - SciY, housed within the newly established Integrated Data Solutions Division of the Bruker BioSpin Group. SciY consolidates all current vendor agnostic software platform and solution brands, and will encompass future innovations born from this collaborative synergy. A key motivation for SciY is to forge new and innovative, modular software solution platforms, meticulously tailored to meet the specific needs of their target markets and applications. Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments. Please use one of the following formats to cite this article in your essay, paper or report: The future of chromatographic data systems: Enabling seamless HPLC-UV method transfer. "The future of chromatographic data systems: Enabling seamless HPLC-UV method transfer". "The future of chromatographic data systems: Enabling seamless HPLC-UV method transfer". The future of chromatographic data systems: Enabling seamless HPLC-UV method transfer. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. Azthena may occasionally provide inaccurate responses. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment." Led by Uzma Saqib - with corresponding author Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya - the perspective reviews recent clinical and translational advances in chimeric antigen receptor T-cell (CAR-T) therapy and highlights both its promise and its remaining barriers. The piece synthesizes recent clinical advances in hematologic malignancies and emerging applications in solid tumors, while focusing attention on safety (for example, cytokine release syndrome and neurotoxicity), resistance, antigen specificity, and access disparities. The authors summarize the CAR-T workflow (leukapheresis → genetic modification and expansion → infusion) and note major recent clinical gains - including improved outcomes in leukemia, lymphoma, and multiple myeloma - that support wider adoption of cellular immunotherapy approaches. They emphasize that despite these advances, important clinical challenges remain, particularly for solid tumors, where antigen selection, tumor microenvironment, and T-cell trafficking limit efficacy. At the same time, the perspective highlights technological and clinical strategies under development to overcome these obstacles, including next-generation CAR designs and improved supportive-care protocols. "Despite its promise, CAR T-cell therapy faces several critical challenges." The authors call out clear next steps for the field: (1) continued refinement of CAR constructs (dual-targeting, switchable/on-off systems, armored CARs) to improve specificity and reduce on-target/off-tumor toxicity; (2) improved management protocols and prophylactic measures to mitigate CRS and neurotoxicity; (3) expanded investigation of allogeneic or alternative CAR-T platforms to address manufacturing, cost, and access barriers; and (4) focused translational studies to improve T-cell trafficking and efficacy in solid tumors. CAR-T therapy: Trailblazing CAR(ing) in cancer treatment. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Researchers at University of California San Diego School of Medicine have developed a new, easy-to-use blood test score that can help identify when fatty liver disease is being driven by excessive alcohol use, an important distinction that often goes unrecognized in routine care. The study results, published in the February 25, 2026 online edition of Gastroenterology, found that a new blood test score could help clinicians determine when liver injury is likely driven by alcohol rather than metabolic factors, providing clearer guidance on when additional alcohol testing may be needed. The tool, called the MetALD-ALD Prediction Index (MAPI), uses five standard lab values that are already collected during most primary care and liver clinic visits. With this information, the score can estimate whether a person with fatty liver disease may have alcohol-related liver injury, even when alcohol use is underreported by the patient. By identifying hidden risk, MAPI gives care teams a head start to intervene early, guide lifestyle changes, and modify treatments with more personalized care. This new score gives clinicians a simple and accessible way to uncover hidden alcohol-related liver injury. The study analyzed more than 500 adults in the San Diego region and about 1,800 individuals in Sweden, showing that MAPI outperformed commonly used blood tests and could help determine when more advanced alcohol testing is needed. Fatty liver disease affects nearly one in three adults worldwide and has multiple causes. Because people often underreport drinking due to stigma or fear, health care providers may miss the role alcohol plays in disease progression. The research team emphasized that while the most accurate alcohol test, called phosphatidylethanol (PEth), is highly reliable, it can be costly or unavailable in many settings. MAPI helps clinicians identify when PEth testing is necessary, making liver disease evaluation more accessible. Researchers say the tool could be especially helpful in primary care settings, where most cases of fatty liver disease are first identified. It may also improve patient counseling by offering a clearer understanding of their condition. This transparency can reduce stigma, empower patients, and encourage honest conversations about alcohol use. "Our goal was to build something practical," added study first author Federica Tavaglione, MD, PhD. "These lab values are already part of standard care, so MAPI can be implemented immediately without adding cost or complexity for clinics." The study was conducted at the UC San Diego MASLD Research Center, which is recognized for its leadership in metabolic and alcohol-associated liver disease research. The MetALD-ALD Prediction Index: A Phosphatidylethanol-Driven Biomarker Panel for Identifying Individuals With Steatotic Liver Disease and Excessive Alcohol Use. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Please do not ask questions that use sensitive or confidential information.

A major new study, led by Queen Mary University of London and funded by the National Institute for Health and Care Research (NIHR) has been published in The Lancet Public Health. It found that out of the five million surgical procedures performed each year by the NHS, around 300,000 are carried out on individuals considered high-risk, and within 90 days of surgery, these high-risk patients account for: While surgery is safer than ever for most people and remains the best treatment option for many conditions, this study highlights the urgent need to identify high-risk patients earlier, to provide care that is better tailored to their individual needs, and for doctors and patients to have more open, honest conversations about the risks and long-term outcomes for surgery at an individual level. It also shows that high-risk patients, who tend to be older and live with several long-term health conditions such as heart disease, have poor outcomes not because of technical failings in surgery or anesthesia, but due to post-operative complications relating to chronic health conditions, age and frailty. Rupert Pearse, Professor and Consultant in Intensive Care Medicine at Queen Mary University of London and Barts Health NHS Trust, and co-lead of the study said: "While surgery is safer than ever before, our findings clearly show that high-risk patients are more likely to have poor outcomes and experience harm after surgery than those deemed low-risk. "Although these patients make up fewer than one in ten surgical cases, their numbers are increasing as the population ages and more people live longer with chronic illness. It is therefore vital that we work to improve care for this group of patients, pre- and post-surgery, including having open conversations with patients about the individual risk of their procedure." He continues: "For many years, surgical success has often been judged by survival at thirty days. Our study shows that this measure does not give the full picture of what happens to many high-risk patients in the months and years after surgery. By looking at longer-term survival and other factors such as time spent in hospital and quality of life, we could make a real difference to patients and potentially help relieve pressure on the wider NHS." Surgery and anesthesia are safer today than ever before, helping to save and improve the lives of millions of people across the UK every year. The Royal College of Anaesthetists is working to improve specialist perioperative care services for high-risk patients, so we can provide each person the tailored care they need to have the best chance of a good outcome after their surgery." Long-term outcomes for patients at high risk of death after surgery in the UK: a retrospective cohort study. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

This article discusses the health potential of duckweed, its biochemical characteristics, clinical evidence, and safety profile. Duckweed (Lemnaceae) is an emerging sustainable plant protein source that provides all essential amino acids, demonstrates short-term human bioavailability, and shows in vitro bioactive potential. Under optimal conditions, duckweed can double its biomass in approximately 2–3 days.1,4 Reported protein content ranges between approximately 20–45% of dry weight depending on species and cultivation conditions, with lower values also reported under suboptimal nutrient availability1,6,7. Annual dry matter yields of up to approximately 30–40 tons per hectare have been described in intensive pilot and controlled systems; however, standardized large-scale agronomic comparisons remain limited.1,7 Protein productivity per unit land area may exceed soybean under optimized systems; however, comparative estimates depend strongly on cultivation parameters and system design, and direct field-equivalent comparisons are not yet comprehensively validated.1,7 The dominant protein in duckweed is ribulose-1,5-bisphosphate carboxylase/oxygenase (RuBisCO), accounting for approximately 40–50% of total protein.6 Duckweed provides all essential amino acids and has been reported to meet FAO amino acid reference patterns for human nutrition, based primarily on compositional analyses rather than standardized DIAAS trials.1,2 Protein content varies significantly across species and growth conditions; for example, Lemna minor and Wolffia globosa have been reported within the 30–45% dry weight range under optimized cultivation, though values below 30% have also been documented.1,6,7 In a randomized controlled trial, consumption of 30 g protein from Wolffia globosa (Mankai strain) significantly increased circulating essential amino acids postprandially, with responses comparable to cheese and peas for most EAAs.2 Branched-chain amino acids increased significantly from baseline, although increases were greater following cheese consumption, reflecting differences in amino acid kinetics rather than necessarily overall protein quality superiority.2 The same RCT demonstrated that Mankai significantly increased serum vitamin B12 concentrations compared with cheese and peas, confirming bioavailability; however, the trial duration was short and does not establish long-term B12 status maintenance.2 Duckweed contains iron, zinc, carotenoids, polyphenols, and dietary fiber.1,4,7 However, mineral composition is highly dependent on cultivation medium due to the plant's strong bioaccumulation capacity, and concentrations of trace elements can vary substantially between production batches.8 Human data indicate protein digestibility of approximately 89%, as reported in review literature synthesizing available experimental data.3 It should be noted that the cited RCT measured postprandial amino acid responses rather than true ileal digestibility coefficients. Bioactive peptides derived from duckweed protein extracts demonstrate antioxidant and anti-inflammatory activity in vitro; however, these findings are based on cellular assays and cannot be directly extrapolated to clinical efficacy without human intervention trials.5,6 Protein quality metrics suggest moderate-to-high quality plant protein, but standardized Digestible Indispensable Amino Acid Score (DIAAS) measurements specific to duckweed strains remain limited in the current literature.2,6 Antioxidant capacity correlates with phenolic content and is influenced by processing methods, reinforcing the importance of production protocol in determining functional outcomes.4,5 Duckweed cultivation supports nutrient recycling, wastewater remediation, and reduced land competition.6,7 Integration into circular food systems may improve sustainability relative to livestock-derived protein, although comprehensive life-cycle assessment data directly comparing duckweed to established protein systems remain limited.6,7 The Panel also noted potential allergenicity due to protein content and emphasized that trace element concentrations depend strongly on cultivation conditions, necessitating strict production controls and monitoring.8 Duckweed represents a promising sustainable plant protein with favorable amino acid composition and demonstrated short-term human bioavailability. Hugo Francisco de Souza is a scientific writer based in Bangalore, Karnataka, India. He is currently pursuing his Ph.D. from the Centre for Ecological Sciences, Indian Institute of Science, where he studies the origins, dispersal, and speciation of wetland-associated snakes. Hugo has received, amongst others, the DST-INSPIRE fellowship for his doctoral research and the Gold Medal from Pondicherry University for academic excellence during his Masters. His research has been published in high-impact peer-reviewed journals, including PLOS Neglected Tropical Diseases and Systematic Biology. When not working or writing, Hugo can be found consuming copious amounts of anime and manga, composing and making music with his bass guitar, shredding trails on his MTB, playing video games (he prefers the term ‘gaming'), or tinkering with all things tech. Please use one of the following formats to cite this article in your essay, paper or report: Duckweed Protein Benefits: Is This Aquatic Plant a Sustainable Superfood?. "Duckweed Protein Benefits: Is This Aquatic Plant a Sustainable Superfood?". Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Please do not ask questions that use sensitive or confidential information.

Researchers at the University of Granada have revealed that the Nutri-Score labeling system, commonly used in Europe to assess food quality, is unable to adequately reflect the nutritional and metabolic complexity of soluble cocoa sold in Spain. The study, which is a pioneer internationally for integrating non-targeted metabolomics techniques applied to the evaluation of nutritional labeling systems, analyzed 54 products from 19 different brands with Nutri-Score ratings between A and D. The analysis confirms that Nutri-Score classifies products primarily based on their sugar, saturated fat, salt, and calorie content. "However, it overlooks relevant molecules associated with beneficial effects, such as phenolic compounds, bioactive peptides, and antioxidant compounds found in cocoa," explains Marta Palma, a researcher in the Department of Nutrition and Food Science at the UGR. In several identified cases, foods with higher cocoa content and more bioactive compounds - and therefore potentially healthier - are penalized with lower ratings (C or D), while other highly processed foods with added sweeteners, thickeners, flavorings, or flours receive a Nutri-Score A, the highest rating. Specifically, some "no added sugar" products, despite being highly processed and containing numerous additives, have better scores than 100% pure cocoa. Scientists have identified peptides, flavonoids, fatty acids, phenols, and other metabolites with potential anti-inflammatory, antioxidant, cardioprotective, or neuroprotective effects. The results highlight the limitations of current front-of-package labeling systems and underscore the need to incorporate additional information such as metabolomics to provide consumers with a more realistic view of nutritional quality. Our work shows that the Nutri-Score system does not capture the complexity of foods rich in bioactive compounds, such as cocoa, which can lead to misinterpretations by consumers. Metabolomics is emerging as a key tool for developing more comprehensive labeling systems that integrate not only macronutrients but also physiologically relevant compounds." This research based on experimental data is the first application of untargeted metabolomics to assess the consistency between nutritional labeling and the actual chemical composition of foods such as soluble cocoa. Its conclusions are particularly relevant for regulatory bodies, the food industry, and consumers, in a context where the future of Nutri-Score in the European Union is under debate. Untargeted metabolomics approaches challenge the nutri-score FOPNL system in soluble cocoa products. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Positioning The University of Texas at San Antonio as a national anchor for aging and longevity science, its Sam and Ann Barshop Institute for Longevity and Aging Studies will receive up to $38 million in federal funding for the first nationwide clinical study in healthy longevity.The Advanced Research Projects Agency for Health (ARPA-H), an agency of the U.S. Department of Health and Human Services, announced the contract to the Barshop Institute at UT Health San Antonio, the academic health center of UT San Antonio, cementing its standing as the nation's leading authority in longevity science. Specifically, the Barshop Institute will use the VITAL-H trial to study the medications rapamycin, dapagliflozin and semaglutide, which based on strong preclinical evidence, promising early human data and extensive post-marketing safety experience may positively affect age-related decline in quality of life and lifespan. VITAL-H will help show whether we can preserve everyday abilities during a critical window of midlife aging." And it is further evidence of UT San Antonio's growing national research standing, providing a platform for the next decade of leadership in aging science. "Today, that foundational science has matured into a national clinical research effort – led from San Antonio – that will shape the future of human health and longevity. "Barshop Institute director Elena Volpi, MD, PhD, who along with her team of investigators are nationally recognized leaders in healthy longevity research, will head the new effort. "Over the past 50 years, global life expectancy has increased substantially, yet the age of onset of age-related diseases and disabilities has remained largely unchanged," Volpi said. "Our population is living longer but with declining function, increased disability and reduced quality of life with major implications for healthcare utilization, caregiver burden and societal costs. Despite major advances in the biology of aging, no FDA-approved interventions currently exist to delay the onset of age-related functional decline or preserve health span in otherwise healthy adults. "This work is focused on changing that trajectory," she said, "advancing science that can help people live not just longer lives, but healthier ones in the decades ahead. "The PROSPR program is intended to identify biochemical and physiological markers and develop assessment tools that allow researchers to better understand and target the underlying causes of age-related disease and build interventions focused on maintaining health during aging.The FDA-approved rapamycin, dapagliflozin and semaglutide medications all have distinct mechanisms of action, are orally administered and have favorable safety profiles at low doses, enabling long-term use in generally healthy populations.The trial is designed to deliver evidence on whether repurposed, FDA-approved drugs can slow age-related decline in generally healthy older adults as well as provide the first large-scale validation of Intrinsic Capacity, which is the concept for healthy aging addressing a person's physical and mental capabilities. Intrinsic Capacity is evaluated by testing cognition, mobility (locomotor), psychological, vitality and sensory functions, to gauge health in aging individuals.The VITAL-H trial will use wearable technologies to monitor the study population selected to capture a critical window in which functional decline is measurable, yet disease burden remains relatively low. "By reframing aging as a modifiable functional trajectory rather than an inevitable accumulation of disease, the study establishes a scalable, regulatory-grade framework for preventive interventions that could possibly inform future clinical development and positively affect people's lives as they age," Volpi said.Clinical trials targeting aging have previously focused on treatment after disease onset, are often underpowered, and rely on narrow or single-modality clinic-based outcomes that limit sensitivity, generalizability and scalability. The University of Texas at San Antonio Health Science Center Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Please do not ask questions that use sensitive or confidential information.

A new study published in the journal Addiction shows that cannabis use among Swedish adolescents appears to follow the same population-level pattern previously observed for alcohol. The researchers examined how frequently adolescents who already use cannabis do so, and how the distribution of use has changed over time. A key finding is that the distribution of cannabis use has remained highly stable over time. When average use increases or decreases, the change occurs in parallel across all user groups. "Increases in average use are not driven solely by a small group of heavy users, but by broader changes in behavior among users in general," says Thor Norström, co-author and Professor Emeritus at the Swedish Institute for Social Research at Stockholm University. The study also shows that periods of higher average use coincide with a marked increase in the proportion of adolescents who use cannabis very frequently. The findings support the so-called total consumption model, a theory that has had a major influence in alcohol research and emphasizes that preventive efforts cannot be limited to high-risk groups alone. Instead, interventions must target the entire population, as changes in norms, availability, and attitudes affect all users simultaneously. "Our results suggest that adolescent cannabis use is characterized by collective changes, in which social networks, norms, and the broader societal climate play an important role," says Håkan Leifman, co-author and researcher at the Department of Clinical Neuroscience at Karolinska Institutet. Even in a country like Sweden, where cannabis remains illegal, changing norms may influence adolescent behavior. "This underscores the importance of a broad public health perspective in preventive efforts targeting cannabis use among young people," says Thor Norström. Norström T and Leifman H. Does the total consumption model apply to cannabis use? Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.